Verastem halts enrollment in study

Verastem Inc. (Nasdaq: VSTM) stopped enrollment in a Phase 2 registration-directed, double-blind, placebo-controlled study of VS-6063 for patients with mesothelioma sending the stock price plummeting $3.82 to close at $1.85.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.